Abstract：Levodopa-induced dyskinesia is a complication caused by long-term treatment of Levodopa in patients with Parkinson’s disease. The treatment of Levodopa-induced dyskinesia is mainly divided into two parts, drug therapy and non-drug therapy. In non-drug therapy, deep brain stimulation and unilateral pallidotomy is considered to be effective. Drug therapy focuses on providing continuous dopaminergic stimulation, such as the development of new Dopamine preparations, catechol-O-methyltransferase inhibitors, Subcutaneous Apomorphine and Levodopa-carbidopa enteral gel continuous jejunal infusion, the second is the use of non-dopaminergic drugs such as Amantadine, Clozapine and Levetiracetam. Although the preclinical results of most non-dopaminergic drugs are encouraging, however, due to the uncertainty of its effect and its side effects, at present, the transformation to clinical practice is still challenging. This article describes in detail the latest treatment of Levodopa-induced dyskinesia at home and abroad, so as to provide reference for daily clinical work.
仲喆 徐敏 陈韦洁 高欢 叶民. 帕金森病异动症治疗进展[J]. 中国医药导报, 2021, 18(14): 39-42.
ZHONG Zhe XU Min CHEN Weijie GAO Huan YE Min. Progress in the treatment of dyskinesia in Parkinson’s disease. 中国医药导报, 2021, 18(14): 39-42.
[1] Tysnes OB，Storstein A. Epidemiology of Parkinson’s disease [J]. J Neural Transm （Vienna），2017，124（8）：901-905.
[2] Ahlskog JE，Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature [J]. Mov Disord，2001，16（3）：448-458.
[3] Bastide MF，Meissner WG，Picconi B，et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease [J]. Prog Neurobiol，2015， 132：96-168.
[4] Picconi B，De Leonibus E，Calabresi P. Synaptic plasticity and levodopa-induced dyskinesia：electrophysiological and structural abnormalities [J]. J Neural Transm（Vienna），2018，125（8）：1263-1271.
[5] Fox SH，Katzenschlager R，Lim SY，et al. International Par-kinson and movement disorder society evidence-based medicine review：Update on treatments for the motor symptoms of Parkinson’s disease [J]. Mov Disord，2018， 33（8）：1248-1266.
[6] Xu H，Zheng F，Krischek B，et al. Subthalamic nucleus and globus pallidus internus stimulation for the treatment of Parkinson’s disease：A systematic review [J]. J Int Med Res，2017，45（5）：1602-1612.
[7] Li X，Zhuang P，Li Y. Altered Neuronal Firing Pattern of the Basal Ganglia Nucleus Plays a Role in Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease [J]. Front Hum Neurosci，2015，9：630.
[8] Russmann H，Ghika J，Combrement P，et al. L-dopa-induced dyskinesia improvement after STN-DBS depends upon medication reduction [J]. Neurology，2004，63（1）：153-155.
[9] Ramirez-Zamora A，Ostrem JL. Globus Pallidus Interna or Subthalamic Nucleus Deep Brain Stimulation for Parkinson Disease：A Review [J]. JAMA Neurol，2018，75（3）：367-372.
[10] Liu Y，Li F，Luo H，et al. Improvement of Deep Brain Stimulation in Dyskinesia in Parkinson’s Disease：A Meta-Analysis [J]. Front Neurol，2019，10：151.
[11] Vitek JL，Bakay RA，Freeman A，et al. Randomized trial of pallidotomy versus medical therapy for Parkinson’s disease [J]. Ann Neurol，2003，53（5）：558-569.
[12] Esselink RA，de Bie RM，de Haan RJ，et al. Long-term superiority of subthalamic nucleus stimulation over pallidotomy in Parkinson disease [J]. Neurology，2009，73（2）：151-153.
[13] Müller T，M?觟hr JD. Efficacy of carbidopa-levodopa extended-release capsules （IPX066） in the treatment of Parkinson Disease [J]. Expert Opin Pharmacother，2018， 19（18）：2063-2071.
[14] LeWitt PA，Giladi N，Navon N. Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa （Accordion Pill?誖） in Parkinson’s disease [J]. Parkinsonism Relat Disord，2019，65：131-138.
[15] Freitas ME，Ruiz-Lopez M，Fox SH. Novel Levodopa Formulations for Parkinson’s Disease [J]. CNS Drugs，2016， 30（11）：1079-1095.
[16] Ferreira JJ，Lees AJ，Poewe W，et al. Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease [J]. Neurology，2018，90（21）：e1849-e1857.
[17] Grandas F. Subcutaneous infusions of apomorphine：a reappraisal of its therapeutic efficacy in advanced Parkinson’s disease [J]. Expert Rev Neurother，2013，13（12）：1343-1353.
[18] Dafsari HS，Martinez-Martin P，Rizos A，et al. EuroInf 2：Subthalamic stimulation，apomorphine，and levodopa infusion in Parkinson’s disease [J]. Mov Disord，2019，34（3）：353-365.
[19] Katzenschlager R，Poewe W，Rascol O，et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations （TOLEDO）：a multicentre，double-blind，randomised，placebo-controlled trial [J]. Lancet Neurol，2018，17（9）：749-759.
[20] Olanow CW，Kieburtz K，Odin P，et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease：a randomised，controlled，double-blind，double-dummy study [J]. Lancet Neurol，2014，13（2）：141-149.
[21] Fernandez HH，Boyd JT，Fung VSC，et al. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson’s disease [J]. Mov Disord，2018，33（6）：928-936.
[22] Meloni M，Solla P，Mascia MM，et al. Diphasic dyskinesias during levodopa-carbidopa intestinal gel（LCIG） infusion in Parkinson’s disease [J]. Parkinsonism Relat Disord，2017，37：92-96.
[23] Solla P，Fasano A，Cannas A，et al. Dopamine agonist withdrawal syndrome （DAWS） symptoms in Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel infusion [J]. Parkinsonism Relat Disord，2015，21（8）：968-971.
[24] Schwab R，England A，Poskanzer D，et al. Amantadine in the treatment of Parkinson’s disease [J]. JAMA，1969， 208（7）：1168-1170.
[25] Hubsher G，Haider M，Okun MS. Amantadine：the journey from fighting flu to treating Parkinson disease [J]. Neurology，2012，78（14）：1096-1099.
[26] Pahwa R，Tanner CM，Hauser RA，et al. ADS-5102 （Amantadine） Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease （EASE LID Study）：A Randomized Clinical Trial [J]. JAMA Neurol，2017，74（8）：941-949.
[27] Durif F，Debilly B，Galitzky M，et al. Clozapine improves dyskinesias in Parkinson disease：a double-blind，placebo-controlled study [J]. Neurology，2004，62（3）：381-388.
[28] Grosch J，Winkler J，Kohl Z. Early Degeneration of Both Dopaminergic and Serotonergic Axons - A Common Mechanism in Parkinson’s Disease [J]. Front Cell Neurosci，2016，10：293.
[29] Hack N，Fayad SM，Monari EH，et al. An eight-year clinic experience with clozapine use in a Parkinson’s disease clinic setting [J]. PLoS One，2014，9（3）：e91545.
[30] Stathis P，Konitsiotis S，Tagaris G，et al. VALID-PD Study Group. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson’s disease [J]. Mov Disord，2011，26（2）：264-270.
[31] Ebada MA，Alkanj S，Ebada M，et al. Safety and Efficacy of Levetiracetam for the Management of Levodopa- Induced Dyskinesia in Patients with Parkinson’s Disease：A Systematic Review [J]. CNS Neurol Disord Drug Targets，2019，18（4）：317-325.
京公网安备 11010502046598号